제논 파마슈티컬스(Xenon Pharmaceuticals Inc.)
DE ˙ DB ˙ CA98420N1050
€45.60 ↑1.00 (2.24%)
2026-06-04
주가
SecurityDE:XP0 / Xenon Pharmaceuticals Inc.
InstitutionEverSource Wealth Advisors, LLC
Latest Disclosed Ownership77 shares
Latest Disclosed Value $ 4,478
EverSource Wealth Advisors, LLC reports 63.68% decrease in ownership of XP0 / Xenon Pharmaceuticals Inc.

On May 15, 2026 - EverSource Wealth Advisors, LLC filed a 13F-HR/A form disclosing ownership of 77 shares of Xenon Pharmaceuticals Inc. (DE:XP0) valued at $3,696 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 212 shares of Xenon Pharmaceuticals Inc.. This represents a change in shares of -63.68% during the quarter. The current value of the position is $3,511 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F/A-1 XENON PHARMACEUTICALS INC COM Stock 98420N105 77 -135 -63.68 4 -55.56 0.0000
2026-05-14 2026-03-31 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 1,074 862 61 0.0003
2026-02-06 2025-12-31 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 212 172 430.00 10 800.00 0.0003
2025-11-10 2025-09-30 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 40 14 53.85 2 0.0001
2025-08-13 2025-06-30 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 26 -32 -55.17 1 -100.00 0.0000
2025-05-13 2025-03-31 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 58 28 93.33 2 0.00 0.0001
2025-02-10 2024-12-31 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 30 -388 -92.82 1 -93.75 0.0001
2024-11-08 2024-09-30 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 418 347 488.73 16 433.33 0.0010
2024-08-13 2024-06-30 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 71 -93 -56.71 3 -50.00 0.0002
2024-06-11 2024-03-31 13F/A-1 XENON PHARMACEUTICALS INC COM Stock 98420N105 164 118 256.52 7 200.00 0.0005
2024-05-13 2024-03-31 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 46 0 2 0.0001
2024-02-09 2023-12-31 13F XENON PHARMACEUTICALS INC COM Stock 98420N105 46 46 2 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.